^
BIOMARKER:

HER-2 positive

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
Curr Probl Cancer - 5 days
HER-2 positive
Gastric Cancer
nivolumab
Resistant: B - Late Trials
Cancer Med - 1 week
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
N Z Med J - 1 week
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A1 - Approval
Chugai Press Release - 1 week
HER-2 positive
HER2 Positive Breast Cancer
KN026
Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 1 week
HER-2 positive
CRC
HER2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
Cell Death Dis - 1 week
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
SABCS 2021 - 2 weeks
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
Future Oncol - 3 weeks
HER-2 positive
Gastric Cancer
trastuzumab + ramucirumab + ALX148
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
HER-2 positive
HER2 Positive Breast Cancer
HER2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
HER-2 positive
HER2 Positive Breast Cancer
AB-201
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TCH
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HER-2 positive
GastroEsophageal Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
Endometrial Cancer
trastuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
HER2 inhibitor
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
AC-TH
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER2 inhibitor
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
AC-THP
Sensitive: A2 - Guideline
HER-2 positive
HER2 Positive Breast Cancer
TH
Sensitive: A2 - Guideline
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
Gastric Cancer
trastuzumab + pertuzumab
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: B - Late Trials
HER-2 positive
Urothelial Cancer
disitamab vedotin
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
SYD985
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
TX05 (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
EG12014 (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: B - Late Trials
HER-2 positive
Small Cell Lung Cancer
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Endometrial Adenocarcinoma
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
NSCLC
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
HER-2 positive
GastroEsophageal Cancer
pembrolizumab + trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Colon Cancer
ado-trastuzumab emtansine
Sensitive: C1 - Off-label
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
HER-2 positive
Solid Tumor
neratinib
Resistant: C1 - Off-label
HER-2 positive
Gastric Cancer
ado-trastuzumab emtansine
Sensitive: C1 - Off-label
HER-2 positive
Esophageal Squamous Cell Carcinoma
trastuzumab
Sensitive: C1 - Off-label
HER-2 positive
Biliary Tract Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: C1 - Off-label
HER-2 positive
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C1 - Off-label
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
paclitaxel
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
margetuximab + MGD013
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
PRS-343
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
epirubicin
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
paclitaxel
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
HM 78136B
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Solid Tumor
KN046 + KN026
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
neratinib + ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 positive
CRC
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
pyrotinib + SHR6390
Sensitive: C2 – Inclusion Criteria
HER-2 positive
GastroEsophageal Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
afatinib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
A166
Sensitive: C2 – Inclusion Criteria
HER-2 positive
CRC
A166
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
ARX788
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + copanlisib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
ASLAN001
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
BAT8001
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
albumin-bound paclitaxel
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
palbociclib + ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Solid Tumor
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Solid Tumor
pyrotinib + SHR6390
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
trastuzumab + ramucirumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
rivoceranib
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + atezolizumab
Sensitive: C2 – Inclusion Criteria
HER-2 positive
HER2 Positive Breast Cancer
HP + eribulin mesylate
Sensitive: C2 – Inclusion Criteria
HER-2 positive
Gastric Cancer
MRG002
Sensitive: C2 – Inclusion Criteria